Compare MHH & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHH | IMMP |
|---|---|---|
| Founded | 1986 | 1987 |
| Country | United States | Australia |
| Employees | N/A | 51 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.6M | 76.6M |
| IPO Year | 2008 | 2012 |
| Metric | MHH | IMMP |
|---|---|---|
| Price | $6.26 | $0.47 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 22.0K | ★ 1.2M |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $191,371,000.00 | N/A |
| Revenue This Year | N/A | $445.09 |
| Revenue Next Year | $9.07 | N/A |
| P/E Ratio | $122.80 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.51 | $0.29 |
| 52 Week High | $8.37 | $3.53 |
| Indicator | MHH | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 44.97 | 41.99 |
| Support Level | $5.53 | $0.42 |
| Resistance Level | $7.11 | $1.05 |
| Average True Range (ATR) | 0.42 | 0.03 |
| MACD | -0.11 | 0.02 |
| Stochastic Oscillator | 43.38 | 39.47 |
Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. The IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.